A potent, broad-spectrum antiviral agent that targets viral membranes

Viruses

Volumn 2, Issue 5, 2010, Pages 1106-1109

  Wojcechowskyj, Jason A ^a   Doms, Robert W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ARBIDOL; BEHENYL ALCOHOL; COSALANE; FAVIPIRAVIR; LIPOSOME; LJ 001; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG FORMULATION; EBOLA HEMORRHAGIC FEVER; ENZYME INHIBITION; FATTY ACID SYNTHESIS; HERPES LABIALIS; HUMAN; HYDROPHOBICITY; INFLUENZA; LIFE CYCLE; LIPID MEMBRANE; NIPAH VIRUS; NONHUMAN; RESPIRATORY TRACT INFECTION; RIFT VALLEY FEVER; VIRION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS REPLICATION;

EID: 79952091466     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2051106     Document Type: Article

References (15)

1. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 2002, 1, 13-25.
2. Johnson, E.M.; Doyle, J.D.; Wetzel, J.D.; McClung, R.P.; Katunuma, N.; Chappell, J.D.; Washington, M.K.; Dermody, T.S. Genetic and pharmacologic alteration of cathepsin expression influences reovirus pathogenesis. J. Virol. 2009, 83, 9630-9640.
3. Chandran, K.; Sullivan, N.J.; Felbor, U.; Whelan, S.P.; Cunningham, J.M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005, 308, 1643-1645.
4. Simmons, G.; Gosalia, D.N.; Rennekamp, A.J.; Reeves, J.D.; Diamond, S.L.; Bates, P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 11876-11881.
5. Furuta, Y.; Takahashi, K.; Shiraki, K.; Sakamoto, K.; Smee, D.F.; Barnard, D.L.; Gowen, B.B.; Julander, J.G.; Morrey, J.D. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009, 82, 95-102.
6. Wolf, M.C.; Freiberg, A.N.; Zhang, T.; Akyol-Ataman, Z.; Grock, A.; Hong, P.W.; Li, J.; Watson, N.F.; Fang, A.Q.; Aguilar, H.C.; Porotto, M.; Honko, A.N.; Damoiseaux, R.; Miller, J.P.; Woodson, S.E.; Chantasirivisal, S.; Fontanes, V.; Negrete, O.A.; Krogstad, P.; Dasgupta, A.; Moscona, A.; Hensley, L.E.; Whelan, S.P.; Faull, K.F.; Holbrook, M.R.; Jung, M.E.; Lee, B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 3157-3162.
7. Abdel-Haq, N.; Chearskul, P.; Al-Tatari, H.; Asmar, B. New antiviral agents. Indian J. Pediatr. 2006, 73, 313-321.
8. Holthuis, J.C.; Levine, T.P. Lipid traffic: floppy drives and a superhighway. Nat. Rev. Mol. Cell Biol. 2005, 6, 209-220.
9. Chernomordik, L. Non-bilayer lipids and biological fusion intermediates. Chem. Phys. Lipids 1996, 81, 203-213.
10. Udata, C.; Patel, J.; Pal, D.; Hejchman, E.; Cushman, M.; Mitra, A.K. Enhanced transport of a novel anti-HIV agent--cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers. Int. J. Pharm. 2003, 250, 157-168.
11. Cushman, M.; Golebiewski, W.M.; McMahon, J.B.; Buckheit, R.W., Jr.; Clanton, D.J.; Weislow, O.; Haugwitz, R.D.; Bader, J.P.; Graham, L.; Rice, W.G. Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. J. Med. Chem. 1994, 37, 3040-3050.
12. Katz, D.H.; Marcelletti, J.F.; Pope, L.E.; Khalil, M.H.; Katz, L.R.; McFadden, R. n-docosanol: broad spectrum anti-viral activity against lipid-enveloped viruses. Ann. N. Y. Acad. Sci. 1994, 724, 472-488.
13. Boriskin, Y.S.; Leneva, I.A.; Pecheur, E.I.; Polyak, S.J. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr. Med. Chem. 2008, 15, 997-1005.
14. Pecheur, E.I.; Lavillette, D.; Alcaras, F.; Molle, J.; Boriskin, Y.S.; Roberts, M.; Cosset, F.L.; Polyak, S.J. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry 2007, 46, 6050-6059.
15. Butcher, E.C. Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov. 2005, 4, 461-467.